BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, October 6, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Forge Therapeutics discovers bacterial LpxC inhibitors
To read the full story,
subscribe
or
sign in
.
Infection
Forge Therapeutics discovers bacterial LpxC inhibitors
Sep. 12, 2022
No Comments
Forge Therapeutics Inc. has synthesized new UDP-3-
O
-(
R
-3-hydroxymyristoyl)-
N
-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of Gram-negative bacterial infections.
BioWorld Science
Infection
Patents